Cargando…
Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor
An octahydroisochromene scaffold has been introduced into a known SARS 3CL protease inhibitor as a novel hydrophobic core to interact with the S2 pocket of the protease. An alkyl or aryl substituent was also introduced at the 1-position of the octahydroisochromene scaffold and expected to introduce...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127348/ https://www.ncbi.nlm.nih.gov/pubmed/31926775 http://dx.doi.org/10.1016/j.bmc.2019.115273 |
_version_ | 1783516340785512448 |
---|---|
author | Yoshizawa, Shin-ichiro Hattori, Yasunao Kobayashi, Kazuya Akaji, Kenichi |
author_facet | Yoshizawa, Shin-ichiro Hattori, Yasunao Kobayashi, Kazuya Akaji, Kenichi |
author_sort | Yoshizawa, Shin-ichiro |
collection | PubMed |
description | An octahydroisochromene scaffold has been introduced into a known SARS 3CL protease inhibitor as a novel hydrophobic core to interact with the S2 pocket of the protease. An alkyl or aryl substituent was also introduced at the 1-position of the octahydroisochromene scaffold and expected to introduce additional interactions with the protease. Sharpless–Katsuki asymmetric epoxidation and Sharpless asymmetric dihydroxylation were employed to construct the octahydroisochromene scaffold. The introductions of the P1 site His-al and the substituent at 1-position was achieved using successive reductive amination reactions. Our initial evaluations of the diastereo-isomeric mixtures (16a–d) revealed that the octahydroisochromene moiety functions as a core hydrophobic scaffold for the S2 pocket of the protease and the substituent at the 1-position may form additional interactions with the protease. The inhibitory activities of the diastereoisomerically-pure inhibitors (3a–d) strongly suggest that a specific stereo-isomer of the octahydroisochromene scaffold, (1S, 3S) 3b, directs the P1 site imidazole, the warhead aldehyde, and substituent at the 1-position of the fused ring to their appropriate pockets in the protease. |
format | Online Article Text |
id | pubmed-7127348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71273482020-04-08 Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor Yoshizawa, Shin-ichiro Hattori, Yasunao Kobayashi, Kazuya Akaji, Kenichi Bioorg Med Chem Article An octahydroisochromene scaffold has been introduced into a known SARS 3CL protease inhibitor as a novel hydrophobic core to interact with the S2 pocket of the protease. An alkyl or aryl substituent was also introduced at the 1-position of the octahydroisochromene scaffold and expected to introduce additional interactions with the protease. Sharpless–Katsuki asymmetric epoxidation and Sharpless asymmetric dihydroxylation were employed to construct the octahydroisochromene scaffold. The introductions of the P1 site His-al and the substituent at 1-position was achieved using successive reductive amination reactions. Our initial evaluations of the diastereo-isomeric mixtures (16a–d) revealed that the octahydroisochromene moiety functions as a core hydrophobic scaffold for the S2 pocket of the protease and the substituent at the 1-position may form additional interactions with the protease. The inhibitory activities of the diastereoisomerically-pure inhibitors (3a–d) strongly suggest that a specific stereo-isomer of the octahydroisochromene scaffold, (1S, 3S) 3b, directs the P1 site imidazole, the warhead aldehyde, and substituent at the 1-position of the fused ring to their appropriate pockets in the protease. Elsevier Ltd. 2020-02-15 2019-12-30 /pmc/articles/PMC7127348/ /pubmed/31926775 http://dx.doi.org/10.1016/j.bmc.2019.115273 Text en © 2019 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Yoshizawa, Shin-ichiro Hattori, Yasunao Kobayashi, Kazuya Akaji, Kenichi Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor |
title | Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor |
title_full | Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor |
title_fullStr | Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor |
title_full_unstemmed | Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor |
title_short | Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor |
title_sort | evaluation of an octahydroisochromene scaffold used as a novel sars 3cl protease inhibitor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127348/ https://www.ncbi.nlm.nih.gov/pubmed/31926775 http://dx.doi.org/10.1016/j.bmc.2019.115273 |
work_keys_str_mv | AT yoshizawashinichiro evaluationofanoctahydroisochromenescaffoldusedasanovelsars3clproteaseinhibitor AT hattoriyasunao evaluationofanoctahydroisochromenescaffoldusedasanovelsars3clproteaseinhibitor AT kobayashikazuya evaluationofanoctahydroisochromenescaffoldusedasanovelsars3clproteaseinhibitor AT akajikenichi evaluationofanoctahydroisochromenescaffoldusedasanovelsars3clproteaseinhibitor |